CN111714529A

CN111714529A - Application of acer truncatum seed oil in preparing medicine for improving intestinal flora

Info

Publication number: CN111714529A
Application number: CN202010816582.6A
Authority: CN
Inventors: 陈显扬; 宋王婷; 韩佳睿; 薛腾
Original assignee: Baofeng Biotech Beijing Co ltd
Current assignee: Baofeng Biotech Beijing Co ltd
Priority date: 2020-08-14
Filing date: 2020-08-14
Publication date: 2020-09-29

Abstract

The invention provides application of acer truncatum seed oil in preparing a medicine for improving intestinal flora. A medicine for improving intestinal flora comprises acer truncatum seed oil and a pharmaceutically acceptable carrier. The edible acer truncatum seed oil or the medicine containing the acer truncatum seed oil can effectively improve the intestinal flora and promote the absorption of the organism to nervonic acid.

Description

Application of acer truncatum seed oil in preparing medicine for improving intestinal flora

Technical Field

The invention belongs to the technical field of biology, and particularly relates to application of acer truncatum seed oil in preparation of a medicine for improving intestinal flora.

Background

The acer truncatum seed oil is a vegetable oil processed from seeds of acer truncatum which is a tree species in China, the content of unsaturated fatty acid reaches 92 percent, 3.2011, 22 days, No. 9 document of Ministry of health of the people's republic of China approves the acer truncatum seed oil as a new resource food, and the acer truncatum seed oil formally enters the ranks of edible vegetable oil in China.

Acer truncatum seed oil is a unique resource in China, and 5% -6% of the Acer truncatum seed oil is nervonic acid. Nervonic acid has been discovered for more than 90 years, and the physiological function of nervonic acid is already clear and is important active fatty acid in human bodies. The research of the plant nervonic acid in China is late, but the research has been in direct pursuit in the last two years. Acer truncatum seed oil is taken as a vegetable oil resource rich in nervonic acid, and has recently received attention of relevant scholars and enterprises.

However, can acer truncatum seed oil be supplemented without interfering with intestinal flora? What changes do intestinal flora metabolites? These very important problems have not been clearly studied to date and even few have been demonstrated. Therefore, the invention evaluates the influence of acer truncatum seed oil on intestinal flora and can be used for improving the development and application of intestinal flora medicaments in the future.

Disclosure of Invention

In order to solve the technical problems, the invention provides application of acer truncatum seed oil in preparing a medicine for improving intestinal flora.

In order to achieve the purpose, the invention adopts the following technical scheme that:

application of Acer truncatum seed oil in preparing medicine for improving intestinal flora is provided. The above-mentioned application, preferably, the medicine is acer truncatum seed oil in a pharmaceutically acceptable carrier.

As mentioned above, the medicament can be prepared into various dosage forms, including injection, capsule, tablet, oral liquid or granule.

A medicine for improving intestinal flora comprises Acer Truncatum Bunge seed oil in pharmaceutically acceptable carrier.

The medicament as described above, preferably, the medicament is an injection, a sachet, a tablet, an oral liquid or a granule.

Preferably, the capsule or the oral liquid contains acer truncatum seed oil, the capsule can be a soft capsule or an enteric capsule, and the oral liquid contains the acer truncatum seed oil and sucrose with the amount of more than 60%.

Preferably, the acer truncatum seed oil comprises, by weight, 3.9-4.02 parts of palmitic acid, 0.05-0.09 part of palmitoleic acid, 0.05-0.09 part of heptadecacarbonic acid, 0.03-0.06 part of cis-10-heptadecaenoic acid, 2.28-2.68 parts of stearic acid, 20-23 parts of oleic acid, 28-32 parts of linoleic acid, 0.20-0.32 part of arachidic acid, 0.54-0.9 part of gamma-linolenic acid, 8.0-8.8 parts of cis-11-eicosenoic acid, 1-2 parts of alpha-linolenic acid, 0.2-cis-11, 14-eicosadienoic acid, 0.96 part of tribehoic acid, 18.7 parts of erucic acid, 0.1-0.2 part of cis-11, 14, 17-eicosatrienoic acid, 0.02-0.06 part of triconic acid, 0.13 part of cis-13, 0.01-docosadienoic acid, 0.03-0.5-tetracosanoic acid (0.05-2 parts of tetracosanoic acid).

After taking Acer truncatum seed oil, intestinal flora can be improved to intervene neuroinflammation.

The invention has the beneficial effects that:

the invention provides an application of acer truncatum seed oil in preparing a medicine for improving intestinal flora.

Experimental research shows that the edible acer truncatum seed oil can effectively improve intestinal flora and promote the absorption of nervonic acid by organisms. Meanwhile, microorganisms related to neuroprotection are obviously increased, and microorganisms related to proinflammatory type are obviously reduced, which shows that the neuroinflammation can be intervened by improving the intestinal flora after taking acer truncatum buge oil. After people take acer truncatum seed oil, the lactobacillus is increased, and the ratio of firmicutes to bacteroidetes is reduced, which shows that the acer truncatum seed oil can adjust the dynamic balance of intestinal flora and well improve or reshape the flora.

Drawings

FIG. 1 is a butterfly diagram showing the change in the level of intestinal flora in rats after 7 days of administration of acer truncatum seed oil;

FIG. 2 is a butterfly diagram showing the change in the level of intestinal flora in rats after 7 days of administration of acer truncatum seed oil;

FIG. 3 is a ROC plot in a logistic regression model;

FIG. 4 is a compound with VIP >1 in positive and negative ion mode 7 days after acer truncatum seed oil supplementation;

FIG. 5 is a graph of the scores of (O) PLS-DA in positive and negative ion mode 7 days after supplementation with Acer truncatum seed oil;

FIG. 6 is a S-plot in positive and negative ion mode 7 days after the Acer truncatum seed oil is supplemented;

FIG. 7 is a schematic of the significant changes in lipids in feces after taking Acer truncatum oil;

FIG. 8 ROC plots in a logistic regression model;

FIG. 9 is a butterfly diagram of the change in the level of gut flora after 7 days of administration of acer truncatum seed oil;

FIG. 10 is a butterfly diagram of the change in the level of gut flora after 7 days of human consumption of acer truncatum seed oil.

Detailed Description

The following examples are intended to further illustrate the invention but should not be construed as limiting it. Modifications and substitutions may be made thereto without departing from the spirit and scope of the invention.

The experimental apparatus and reagents used in the examples of the present invention: 1. freezing a centrifuge: model D3024R, Scilogex corporation, usa; 2. a vortex oscillator: model MX-S, Scilogex, USA; 3. high resolution mass spectrometer: ESI-QTOF/MS; the model is as follows: xevo G2-S Q-TOF; the manufacturer: waters, Manchester, UK; 4. ultra-high performance liquid chromatography: UPLC; the model is as follows: the ACQUITY UPLC I-Class system; the manufacturer: waters, Manchester, UK; 5. data acquisition software: MassLynx4.1; the manufacturer: waters; 6. analysis and identification software: prognesis QI; the manufacturer: waters;

experimental reagent: isopropanol, acetonitrile, formic acid, ammonium formate, leucine enkephalin and sodium formate. The manufacturers are Fisher. The acer truncatum seed oil used in the following examples of the present invention was provided by acer truncatum biotechnology (beijing) ltd, the components are detected by a third party detection company, namely Banni, and the detection result comprises, by weight, 4.02 parts of palmitic acid, 0.07 part of palmitoleic acid, 0.07 part of heptadecacarbonic acid, 0.04 part of cis-10-heptadecaenoic acid, 2.48 parts of stearic acid, 21.8 parts of oleic acid, 30.7 parts of linoleic acid, 0.28 part of arachidic acid, 0.74 part of gamma-linolenic acid, 8.54 parts of cis-11-eicosenoic acid, 1.65 parts of alpha-linolenic acid, 0.34 part of cis-11, 14-eicosadienoic acid, 0.96 part of behenic acid, 18.7 parts of erucic acid, 0.16 part of cis-11, 14, 17-eicosatrienoic acid, 0.04 part of tricosanoic acid, 0.02 part of cis-13, 16-docosadienoic acid, 0.42 part of tetracosanoic acid and 6.89 parts of cis-15-tetracosanoic acid (nervonic acid). Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.

Example 1

The experimental study was carried out by randomly dividing 30 male SD rats of 5-6 weeks into 2 groups, each group being Acer truncatum seed oil group (NA group) and normal control group (CK group), feeding for 1 week, and feeding into stomach according to the dose of 0.03g/kg/d nervonic acid calculated by the Acer truncatum seed oil group by the conversion method of the drug dose between human and rat, feeding 1 time per day, and collecting feces after 7 days of continuous administration. The normal group was normally bred and the sampling method was the same as above.

Through earlier studies, the onset time of taking acer truncatum buge seed oil is determined to be 3 days, and the effect is stable on the seventh day. Therefore, the change of the intestinal flora of rats 7 days after taking the acer truncatum buge seed oil is analyzed by a 16S rDNA high-throughput sequencing method, and the effect of taking the acer truncatum buge seed oil on the change of the intestinal flora is examined.

1. Rat fecal sample 16S rDNA sequencing analysis

1.1DNA extraction

A rat fecal sample of 200mg was taken and fecal flora total genomic DNA was extracted strictly according to the Ql Aamp Fast DNA pool Mini Kit instructions.

1.2DNA quality testing

High-quality DNA is the primary requirement for ensuring the sequencing quality of the subsequent library construction, and Multiskan is applied in the experiment^TMThe GO enzyme-labeling instrument is used for quantifying the concentration of DNA and detecting the purity of the DNA, and agarose gel electrophoresis is adopted to detect the integrity of the DNA.

1.3 library construction

The 16Sr DNA sequencing analysis is one of the most widely applied amplicon library-building sequencing methods in the field of microorganisms at present, wherein the V3-V4 region is more researched, and the database information content is relatively rich. The 16S library is built by adopting an Illumina library building strategy, wherein the Illumina library building strategy is adopted for amplifying the 16S V3-V4 region by 341F and 806R primers or amplifying the 16S V4 region by 515F and 806R primers. And quantifying each sample by adopting the Qubit 3.0, and mixing response proportions according to the data volume requirement.

1.4 library quality testing

The library is subjected to strict quality detection to ensure the quality of the library. The quality detection of the library comprises library concentration detection, insert size detection and library molar concentration accurate detection. Library detection mainly comprises 3 methods: (1) quit 3.0 performs preliminary quantification on library concentration (2) Agilent 2100 detects integrity of library DNA fragments and size of insert fragment (3) Q-PCR method performs accurate quantification on library effective concentration

1.5 sequencing on machine

After the library was qualified, different libraries were pocolling to flowcell according to the requirement of effective concentration and target off-machine data volume, and sequenced using Illumina high throughput sequencing platform (Hi Seq/Mini Seq).

2. Analysis of results

The results of the relative abundance changes of the phylum of intestinal flora and the phylum of genus (. P <0.1) after 7 days of supplementation with acer truncatum seed oil are shown in Table 1, and the butterfly diagram is shown in FIG. 1. As can be seen from FIG. 1, the phylum level shows a significant change in the abundance of each phylum of bacteria after 7 days of supplementation with acer truncatum seed oil compared with the control group, and the phylum of Firmicutes, bacteroides and Verrucomicrobia show significant changes, wherein bacteroides shows a significant rising trend, while the phylum of Firmicutes and Verrucomicrobia show a significant falling trend.

TABLE 1 variation of abundance of rat intestinal flora in different phyla of bacteria (mean)

Door level	Normal control group	Acer truncatum oil composition	Significance of
				Thick wall fungus door	66.93	55.58	*
Bacteroides door	25.81	41.01	*
				Wart microsomycota	0.77	0.07	*
Actinomycetes door	2.65	1.61	*
				Deformable bacteria	0.98	1.17
Cyanobacteria phylum	0.21	0.17
				Mollicutes phylum	0.05	0.28

Note: p <0.1 indicates significance.

The abundance of Acer truncatum at the level of Enterobacter group after 7 days of administration of Acer truncatum seed oil to rats is shown in Table 2, the butterfly diagram is shown in FIG. 2, it can be seen from FIG. 2 that the abundance of each phylum of bacteria changes at the genus level after 7 days of supplementation with Acer truncatum seed oil as compared with the control group, and that the genera of Ackermanella (Akkermansia), Ruminococcaceae-UCG-014 (Ruminococcaceae _ UCG-014), Romboutsia, Bacteroides (B acteroides), Prevotella (Prevoteceae _ UCG-001), Lachnospiraceae-NK 4A136(Lachnospiraceae _ NK4A136_ group) and Prevotella-NK 3B31 (Prevotecia _ NK3B31_ group) change significantly, wherein the genera of Aceracoccinella (Akkerimazetaceae), Ruminococcaceae-NK-014 (Lambochacterium) and Prevotella B3B 31(Prevotella _ UC 6319) show a trend, and the trends of Lambochaetobacter .

TABLE 2 variation of abundance of rat intestinal flora under different bacterial genera (mean)

Numbering	Belong to the horizon	Normal control group	Acer truncatum oil composition	Significance of
					1	Lactobacillus strain	40.92	43.79
2	Achromobacter incarnatum	0.77	0.07	*
					3	Ruminococcaceae-UCG-014	2.36	1.09	*
4	Bacteria of Romboutsia	6.29	3.94	*
					5	Bacteroides sp	1.06	4.06	*
6	Muribactaceae-unclassified	6.81	7.04
					7	Clostridium bacteria	2.5	3.58
8	Prevotella UCG-001	3.43	9.73	*
					9	Lachnospiraceae-NK 4A136	2.24	0.36	*
10	Ruminococcus-2	0.05	0.11
					11	Ruminococcus-UCG-013	0.1	0.05
12	Paramunibulum sp	2.68	1.3	*
					13	Erysipeliocalostridium sp	0.2	0.29
14	Prevotella-NK 3B31	1.93	3.75	*
					15	Muribactuu bacteria	1.35	1.63

Note: p <0.1 indicates significance.

In FIG. 2, wherein R1 Lactobacillus (Lactobacillus); r2 akkermansia (Akkerma nsia); r3 Ruminococcaceae-UCG-014 (Ruminococcaceae _ UCG-014); r4 Romb outia; r5 Bacteroides (bacteriodes); r6 muribacteriaceae _ unclassified; r7 Clostridium (Clostridium sense stricoto _ 1); r8 Prevotella (Prevotellaceae _ UC G-001); r9 Lachnospiraceae-NK 4A136(Lachnospiraceae _ NK4A136_ group); r10 Ruminococcus-2 (Ruminococcus _ 2); r11 Ruminococcus-UCG-013 (Ruminoc occicaeae _ UCG-013); r12 Paramuribaculum; r13 erysipeloclotridium; r14 Prevotella-NK 3B31(Prevotellaceae _ NK3B31_ group); r15 muribamulu m (. P < 0.1).

2. Regression model

To investigate whether significantly varying genera were associated with acer truncatum seed oil consumption, a logistic regression model was then established for validation, as shown by the ROC plot in fig. 3:

the model variables were 8 significantly varied genera, including Exendicella (Akkermansia), Ruminococcaceae-UCG-014 (Ruminococcaceae _ UCG-014), Romboutsia, Lachnospiraceae-NK 4A136(Lachnospiraceae _ NK4A136_ group), Paramuricatum, Bacteroides (Bacteroides), Prevotella (Prevotelae _ UCG-001), and Prevotella-NK 3B31 (Prevotelae _ NK3B31_ group).

Sensitivity is 1, Specificity is 1, and Accuracy is 1. The sensitivity, specificity and accuracy in the regression equation are automatically obtained after performing logistic regression through R language.

The model verification result shows that: the model verification result shows that: the difference substances with obvious changes can well explain the change of the intestinal flora after taking acer truncatum buge seed oil. Studies have shown that disturbances in intestinal microbial diversity during the development of alzheimer's disease affect neuroinflammation and amyloidosis. Wherein part of the bacteria of the Ruminococcaceae-UCG-014 and Mupiromyces families are associated with peripheral T cells of the pro-inflammatory type (Th1), microglia of the pro-inflammatory type (M1), and Prevotella (Prevotellaceae _ UCG-001) are associated with peripheral T cells of the neuroprotective type (Th2) and microglia (M2). The result is consistent with the discovery of the invention that after taking acer truncatum buge oil, microorganisms related to neuroprotection are increased, and microorganisms related to proinflammatory type are decreased, which indicates that the acer truncatum buge oil can intervene neuroinflammation by improving intestinal flora after taking the acer truncatum buge oil.

Example 2

The male SD rats of 5-6 weeks old are randomly divided into 2 groups, wherein the groups are Acer truncatum seed oil group (NA group) and normal control group (CK group), the rats are fed for 1 week, the experiment is carried out, the Acer truncatum seed oil group calculates the dosage according to the conversion method of the drug dosage between human and rats, the continuous Acer truncatum seed oil group is administrated 1 time per day according to the gastric lavage of 0.03g/kg/d of contained nervonic acid, and the feces are collected after 7 days of continuous administration. The normal group was normally bred and the sampling method was the same as above. 0.05g of mouse feces was extracted with 600 μ L of pre-cooled isopropanol, vortexed for 1min, incubated at room temperature for 10min, the extraction mixture was then stored overnight at-20 ℃, centrifuged at 4000r for 20min, and the supernatant was transferred to a new centrifuge tube and diluted to 1: 10. samples were stored at-80 ℃ prior to LC-MS analysis.

The change of the feces metabolites of rats 7 days after taking acer truncatum buge seed oil is analyzed by a lipidomics method, and the influence of the change of intestinal flora on the feces metabolites after taking the acer truncatum seed oil is examined.

The specific method comprises the following steps: the samples were analyzed by ACQUITY UPLC (Waters, USA) connected to a Xevo-G2XS high resolution time of flight (QTOF) mass spectrometer (Waters) with ESI. A CQUITY UPLC BEH C18 column (2.1X 100 mM, 1.7 μm, Waters) was used with mobile phases of 10mM ammonium formate-0.1% formic acid-acetonitrile (A, 60: 40, v/v) and 10mM ammonium formate-0.1% formic acid-isopropanol-acetonitrile (B, 90: 10, v/v). Prior to large scale studies, pilot experiments including 10, 15 and 20 minute elution periods were performed to assess the potential impact of mobile phase composition and flow rate on lipid retention time. In PIM, abundant lipid precursor ions and fragments are separated in the same order, with similar peak shapes and ionic strengths. In addition, the mixed QC samples with 10 minute elution periods also showed similar basal peak intensities of precursors and debris as the test samples. The flow rate of the mobile phase was 0.4 mL/min. The column was initially eluted with 40% B, then a linear gradient to 43% B in 2 minutes, then increasing the percentage of B to 50% in 0.1 min. In the next 3.9 minutes, the gradient further increased to 54% B, then the amount of B increased to 70% in 0.1 minutes. In the final part of the gradient, the amount of B increased to 99% in 1.9 min. Finally, solution B returned to 40% in 0.1min and the column was equilibrated for 1.9 min before the next injection. The sample injection amount is 5 mu L each time, and the lipid under the positive and negative modes is detected by a Xevo-G2XS QTOF mass spectrometer, the collection range is 50-1200 years at m/z, and the collection time is 0.2 s/time. The ion source temperature is 120 ℃, the desolventizing temperature is 600 ℃, the gas flow is 1000L/h, and nitrogen is used as flowing gas. The capillary voltage was 2.0kV (+)/cone voltage was 1.5kV (-), and the cone voltage was 30V. Standard mass measurements were performed with leucine enkephalin, calibrated with sodium formate solution. Samples were randomly ordered. One QC sample was injected every 10 samples and analyzed to investigate the reproducibility of the data. 1. Multivariate statistics was used to look for fecal lipid-poor impurities.

Orthogonal partial least squares discriminant analysis (OPLS-DA) combines Orthogonal Signal Correction (OSC) and partial least squares discriminant analysis (PLS-DA) methods to screen for differential variables by removing irrelevant differences. The VIP value is a variable importance projection of a first main component of orthogonal partial least squares discriminant analysis (OPLS-DA), and VIP >1 is usually taken as a common evaluation standard of metabonomics and is taken as one of the standards for screening differential metabolites; the results are shown in FIG. 4, which shows that VIP >1 is A compound in positive and negative ion mode, wherein A is positive ion mode, B is negative ion mode, FIG. 5 is A score map of PLS-DA in positive ion mode, C is A score map of PLS-DA in positive ion mode, (O) N-A represents Acer truncatum seed oil group, CK represents blank control group) and D is A score map of PLS-DA in negative ion mode, the first principal component and the second principal component in the two groups of Acer truncatum seed oil group (N-A) and blank control group (CK represents) are obtained by dimensionality reduction, the abscissA represents the difference between groups, the ordinate represents the difference between groups, and the results of the two groups are better separated, which indicates that the scheme can be used. FIG. 6 is a graph of S-plot in positive and negative ion mode, E is a graph of S-plot in positive ion mode, F is a graph of S-plot in negative ion mode, abscissa represents the co-correlation coefficient of the principal component and metabolite, ordinate represents the correlation coefficient of the principal component and metabolite, and p <0.05, VIP >1 is satisfied, and the negative ion mode has 51 different impurities and the positive ion mode has 7 different impurities. To further narrow the range, lipids or lipid compounds were selected by class analysis for a total of 31 compounds, as shown in table 1.

2. Kyoden analysis

The youden joden index calculation was performed on 31 compounds, and the diagnosis and prediction effect of the individual indices on the whole was reflected by AUC, thereby determining that these indices are molecular markers. The results are shown in Table 1.

TABLE 1 analysis of jotan index of related lipids after supplementation with Acer truncatum seed oil

Table 1 lists the area under the curve (AUC), sensitivity and specificity of predicting the administration of acer truncatum seed oil with individual metabolites, and the results show: the 31 molecular markers have good prediction effect, and comprise 4 lipids containing nerve acid chains, including PE (22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z)), PC (24:1(15Z)/16:0), PE (24:1(15Z)/20:0) and DG (24:1n9/0:0/22:2n 6).

3. Significantly altered lipids in acer truncatum oil feces

Compounds with AUC values greater than 0.8 were selected for a total of 7 compounds and were histogram based on their amount detected in the fecal samples 7 days after the control and acer truncatum seed oil administration, with the results shown in figure 7,

as a result, it was found that the PC (24:1(15Z)/16:0) compound in rats administered with Acer truncatum Bunge seed oil was higher than that in rats not administered. Therefore, the content of lipid containing nervonic acid chains in PC (24:1(15Z)/16:0) is increased compared with the normal group after taking Acer truncatum Bunge oil, which shows that the composition can effectively prevent neuritis.

4. Regression model

To investigate whether significantly varying metabolites were associated with acer truncatum seed oil consumption, a logistic regression model was then established for validation, as shown by the ROC plot in fig. 8:

the model variables were the 7 significantly varied metabolites described above, including Cer (d18:0/20:0), 28-glucopyranosolic enoic acid 3-arabinoside, alispiroside C, TG (20:1(11Z)/14:0/18:3(9Z,12Z,15Z)), PC (24:1(15Z)/16:0), TG (18:4(6Z,9Z,12Z,15Z)/20:2n6/18:4(6Z,9Z,12Z,15Z)), Nonadeca-10(Z) -oienc acid.

Sensitivity is 1, Specificity is 1, and Accuracy is 1. The sensitivity, specificity and accuracy in the regression equation are automatically obtained after performing logistic regression through R language. The model verification result shows that: the obviously changed different substances can well explain the change of the excrement metabolites after taking the acer truncatum seed oil.

Therefore, after taking acer truncatum seed oil, a large number of genera in intestinal flora are changed, 31 kinds of lipids or lipoids in the fecal lipidosome are changed, particularly the content of the lipid containing nervonic acid chains in PC (24:1(15Z)/16:0) is obviously increased, and the change of the intestinal flora after taking the acer truncatum seed oil can promote the absorption and utilization of nervonic acid and can be used for preparing medicines for improving the intestinal flora.

Example 3

1. 10 healthy volunteers aged 20-50 years and having no smoking and drinking history in the last two weeks were recruited, and after 7 days of continuous administration of acer truncatum seed oil (the recommended intake of nervonic acid does not exceed 300 mg/day), feces before and after administration were collected for 16SrDNA sequencing and used as a control before administration.

The experimental procedure and procedure were as in example 1.

2. Analysis of results

The intestinal microorganisms have obvious changes on phylum level and genus level after 7 days of supplementation with acer truncatum seed oil, the abundance changes are shown in table 3, for example, fig. 9 shows the changes on phylum level of the intestinal microorganisms before and after administration, and as can be seen from fig. 9, on phylum level, the abundance of each phylum of bacteria changes after 7 days of supplementation with acer truncatum seed oil compared with that before administration, and the abundance changes are obvious in Firmicutes, Bacteroidetes and Proteobacteria, wherein bacteroides shows a remarkable rising trend, and Firmicutes and Proteobacteria show a remarkable falling trend.

TABLE 3 abundance changes (mean) of human intestinal flora under different phyla of bacteria

Door level	Normal control group	Acer truncatum oil composition	Significance of
				Thick wall fungus door	72.93	57.36	**
Bacteroides door	19.81	41.32	**
				Actinomycetes door	2.25	1.64
Deformable bacteria	0.68	0.14	*
				Wart microsomycota	0.17	0.07
Cyanobacteria phylum	0.38	0.27

Note: indicates p <0.05 very significant, indicates p <0.01 very significant

FIG. 10 shows the change of intestinal microorganisms at genus level before and after administration, and the abundance changes are shown in Table 4, and it can be seen from FIG. 10 that at genus level, Lactobacillus (Lactobacillus), Romboutsia, Bacteroides (Bacteroides), Clostridium (Clostridium _ sensory _ stricotno _1), Prevotella (Prevotella _ UCG-001), Lachnospiraceae-NK 4A136(Lachnospiraceae _ NK4A136_ group), and Paramurabaculum genus change significantly compared to before administration, wherein Romboutsia, Lachnospiraceae-NK 4A136(Lachnospiraceae _ NK4A136_ group), and Paramura bacterium genus show a downward trend, and Lactobacillus (Lactobacillius), Bacteroides (Bacteroides) and Prevotella (Prevotella) show an upward trend.

TABLE 4 abundance variation (mean) of human intestinal flora under different bacterial genera

Note: p <0.05 very significant, p <0.01 very significant

The firmicutes and bacteroidetes are the dominant phyla in humans, and the results show that the ratio of the two is increased and is related to some diseases, the results show that the ratio of firmicutes to bacteroidetes is significantly reduced after taking acer truncatum seed oil, simultaneously, Lactobacillus (Lactobacillus), Bacteroides (Bacteroides) and Prevotella (Prevotella _ UCG-001) are remarkably increased, the Lactobacillus has stronger acid production capability of metabolic carbohydrate, can synthesize glucan and heteropolysaccharide, is a probiotic in human bodies, prevotellaceae can participate in the synthesis of mucin in the mucosal layer of the intestinal tract, and short chain fatty acid with nerve cell nourishing and anti-inflammatory effects is produced by fermentation of soluble fiber, whereas a decrease in Prevotellaceae may lead to a decrease in intestinal mucus and an increase in intestinal permeability, increasing local and systemic susceptibility to bacterial antigens and LPS, thereby inducing a large amount of overexpression and misfolding of alpha-synuclein. Therefore, the acer truncatum seed oil can improve the intestinal flora and regulate the dynamic balance of the intestinal flora when being taken.

The acer truncatum seed oil is prepared into a capsule or a tablet, wherein the tablet is a common absorbent containing acer truncatum seed oil, magnesium carbonate and the like, and the capsule can be prepared into a soft capsule or an enteric capsule by a conventional preparation method.

Claims

1. Application of Acer truncatum seed oil in preparing medicine for improving intestinal flora is provided.

2. The use of claim 1, wherein the medicament is acer truncatum seed oil in a pharmaceutically acceptable carrier.

3. The use according to claim 1, wherein the medicament is an injection, a sachet, a tablet, an oral liquid or a granule.

4. A medicine for improving intestinal flora is characterized by comprising acer truncatum seed oil and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is in the form of an injection, a sachet, a tablet, an oral liquid or a granule.

6. The medicament as claimed in claim 5, wherein the capsule or oral liquid contains Acer Truncatum Bunge seed oil, the capsule can be soft capsule or enteric capsule, the oral liquid contains Acer Truncatum Bunge seed oil and sucrose, and the sucrose content is more than 60%.

7. The use of claim 1, wherein the acer truncatum seed oil comprises, by weight, 3.9 to 4.02 parts of palmitic acid, 0.05 to 0.09 parts of palmitoleic acid, 0.05 to 0.09 parts of heptadecacarbonic acid, 0.03 to 0.06 parts of cis-10-heptadecaenoic acid, 2.28 to 2.68 parts of stearic acid, 20 to 23 parts of oleic acid, 28 to 32 parts of linoleic acid, 0.20 to 0.32 parts of arachidic acid, 0.54 to 0.9 parts of gamma-linolenic acid, 8.0 to 8.8 parts of cis-11-eicosenoic acid, 1 to 2 parts of alpha-linolenic acid, 0.2 to 0.4 parts of cis-11, 14-eicosadienoic acid, 0.96 parts of behenic acid, 18.7 parts of erucic acid, 18.7 parts of cis-11, 14, 17-eicosatrienoic acid, 0.1 to 0.2 parts of tricosanoic acid, 0.02 to 0.06 parts of tricosanoic acid, 0.01 to 13 parts of docosadienoic acid, 0.01 to 0.7 parts of tetracosenoic acid, and 0.05 to 15 parts of tetracosenoic acid.